Table 2.

Oral vaccination with Ad plus adjuvant permits successful readministration

Parametera	Value for group:
	A	B	C	D	E	F
1st vaccination (rAd-GP120) route	p.o.	i.m.	p.o.	i.m.	NAb	NA
Anti-vector titer	<100	1,000–10,000	<100	1,000–10,000	NA	NA
2nd vaccination (rAd-CMV-HA) route	p.o.	p.o.	i.m.	i.m.	p.o.	i.m.
Anti-vector titer (avg)	100	10,000	10,000	100,000	<100	6.4e3
Anti-vector neutralization (±SD)	<10	38.5 ± 48	NDc	65 ± 49	<10	80 ± 44
Anti-HA titer (±SD)	692 ± 721	1,050 ± 464	6,750 ± 4,182	167 ± 147	550 ± 409	9,145 ± 4,182
% HA titer compared to naive	126	190	71	2	100	100

^aMice were vaccinated with 1 × 10⁷ IU of Ad-GP120 vector and the exogenous adjuvant on day 1. Four weeks later, the mice were vaccinated with 1 × 10⁷ IU of rAd-CMV-HA. Anti-vector and anti-HA responses were measured 3 weeks post-vaccination 1 and 2.

^bNA, not applicable.

^cND, not done.